Skip to main content

Table 1 Mean values of probabilities employed in the decision tree

From: Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Strategy Probabilities of relapse over 52 weeks Probabilities of discontinuation of treatment over 52 weeks Probabilities that treatment is best in reducing relapse over 52 weeks (reassessed excluding zotepine) Probabilities of adverse events Probabilities of Diabetes Mellitus complications   
   Intolerable side effects Other reasons   EPS Weight gain Glucose intolerance Diabetes Mellitus Amputation Fatal myocardial infarction Non-fatal myocardial infarction Non-fatal stroke Heart failure Ischaemic heart disease
Amisulpride 0.2988 0.0554 0.2435 0.084 0.3163 0.3175 0.2381 0.0317 0.0023 0.0042 0.0130 0.0039 0.0040 0.0157
Aripiprazole 0.2742 0.1582 0.3520 0.119 0.2258 0.1516 0.1167 0.0156       
Haloperidol 0.3317 0.0922 0.2516 0.035 0.5367 0.2000 0.1500 0.0200       
Olanzapine 0.1996 0.0783 0.2730 0.152 0.2336 0.4172 0.3129 0.0417       
Paliperidone ER 0.1625 0.3287 0.3848 0.525 0.2569 0.2123 0.1592 0.0212       
Risperidone 0.2761 0.0994 0.1761 0.086 0.3546 0.2141 0.1606 0.0214       
  1. EPS: Extra-Pyramidal Symptoms)
  2. ER: Extended-Release
  3. Annual probability of transition of impaired glucose intolerance to diabetes = 0.0196